| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $0 | 0 | 0 |
Sells | $15,588,902 | 53 | 100 |
| Heyman Richard A. | director | 0 | $0 | 4 | $413,379 | $-413,379 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | 0 | $0 | 7 | $653,939 | $-653,939 |
| Kintz Samuel | PRESIDENT AND CEO | 0 | $0 | 12 | $1.79M | $-1.79M |
| Patel Anish | CHIEF OPERATING OFFICER | 0 | $0 | 8 | $2.27M | $-2.27M |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | 0 | $0 | 7 | $4.36M | $-4.36M |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 15 | $6.1M | $-6.1M |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Over the last 12 months, insiders at Enliven Therapeutics, Inc. have bought $0 and sold $15.59M worth of Enliven Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Enliven Therapeutics, Inc. have bought $0 and sold $36.89M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-05-18 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 0.0082% | $39.79 | $198,971 | -0.54% | |
| 2026-04-17 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 0.0083% | $47.67 | $238,352 | -13.82% | |
| 2026-03-25 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 40,000 0.0661% | $35.10 | $1.4M | +17.07% | |
| 2026-03-17 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 0.0084% | $27.76 | $138,800 | +48.31% | |
| 2026-03-10 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 10,129 0.0173% | $30.19 | $305,827 | +35.40% | |
| 2026-03-09 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 29,871 0.0513% | $30.02 | $896,811 | +37.39% | |
| 2026-03-06 | Sale | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 10,000 0.0169% | $29.58 | $295,839 | +38.42% | |
| 2026-02-17 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 45,000 0.076% | $26.17 | $1.18M | +50.34% | |
| 2026-02-17 | Sale | Heyman Richard A. | director | 1,230 0.0021% | $26.18 | $32,196 | +50.34% | |
| 2026-02-06 | Sale | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 5,000 0.0083% | $29.04 | $145,219 | +32.17% | |
| 2026-01-20 | Sale | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 20,000 0.0333% | $26.75 | $535,099 | +35.27% | |
| 2026-01-20 | Sale | Heyman Richard A. | director | 1,230 0.002% | $26.75 | $32,902 | +35.27% | |
| 2026-01-09 | Sale | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 91,198 0.1609% | $27.22 | $2.48M | +32.15% | |
| 2026-01-09 | Sale | Patel Anish | CHIEF OPERATING OFFICER | 48,300 0.0876% | $27.99 | $1.35M | +32.15% | |
| 2026-01-09 | Sale | Heyman Richard A. | director | 4,285 0.0069% | $25.00 | $107,125 | +32.15% | |
| 2026-01-08 | Sale | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 41,302 0.072% | $24.05 | $993,436 | +40.88% | |
| 2026-01-08 | Sale | Heyman Richard A. | director | 9,635 0.0175% | $25.03 | $241,156 | +40.88% | |
| 2025-12-19 | Sale | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 5,000 0.0084% | $16.84 | $84,206 | +76.97% | |
| 2025-12-08 | Sale | Patel Anish | CHIEF OPERATING OFFICER | 6,663 0.0115% | $21.02 | $140,073 | +43.47% | |
| 2025-11-19 | Sale | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 12,008 0.0204% | $22.30 | $267,794 | +30.09% |
| Increased Positions | 66 | +40.74% | 8M | +13.17% |
| Decreased Positions | 74 | -45.68% | 5M | -8.28% |
| New Positions | 20 | New | 2M | New |
| Sold Out Positions | 27 | Sold Out | 3M | Sold Out |
| Total Postitions | 154 | -4.94% | 62M | +4.89% |
| Orbimed Advisors Llc | $123,691.00 | 13.49% | 7.96M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $110,788.00 | 12.08% | 7.13M | -430,705 | -5.7% | 2025-09-30 |
| Commodore Capital Lp | $72,926.00 | 7.95% | 4.69M | 0 | 0% | 2025-09-30 |
| Fairmount Funds Management Llc | $57,676.00 | 6.29% | 3.71M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $54,678.00 | 5.96% | 3.52M | +551,390 | +18.58% | 2025-09-30 |
| Vr Adviser, Llc | $50,137.00 | 5.47% | 3.23M | -800,000 | -19.87% | 2025-09-30 |
| Polar Capital Holdings Plc | $48,096.00 | 5.25% | 3.1M | +44,713 | +1.47% | 2025-09-30 |
| Vanguard Group Inc | $39,674.00 | 4.33% | 2.55M | +142,378 | +5.91% | 2025-09-30 |
| Janus Henderson Group Plc | $27,872.00 | 3.04% | 1.79M | +77,171 | +4.5% | 2025-09-30 |
| Novo Holdings A/S | $22,164.00 | 2.42% | 1.43M | +341,828 | +31.52% | 2025-09-30 |